Subscribe To
TGTX / Why Is TG Therapeutics (TGTX) Stock Down 50% Today?

TGTX News

By The Motley Fool
November 1, 2023
Why TG Therapeutics Stock Is Crushing It Today
The company reported Q3 results that were much better than expected. An up-front licensing payment from Neuraxpharm was a big factor in these surprisi more_horizontal

By Schaeffers Research
November 1, 2023
Biopharmaceutical Stock Soars on Earnings Beat
TG Therapeutics Inc (NASDAQ:TGTX) stock is soaring today, after the biopharmaceutical name's third-quarter results smashed analyst expectations. more_horizontal

By Seeking Alpha
October 16, 2023
TG Therapeutics: Things Are Stacking Up Against Briumvi
TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its e more_horizontal

By Invezz
October 11, 2023
TG Therapeutics (TGTX) stock price has plunged: buy the dip?
TG Therapeutics (NASDAQ: TGTX) stock price sell-off continued this week as concerns about the rising competition continued. The shares plunged to a lo more_horizontal

By Seeking Alpha
October 3, 2023
TG Therapeutics: Racing Against Time While Their Differentiators Are Still Relevant
TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosi more_horizontal

By GlobeNewsWire
September 22, 2023
TG Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET Fireside chat scheduled for Tuesday, September 26, 2023, at 12:25 PM ET more_horizontal

By InvestorPlace
August 1, 2023
Why Is TG Therapeutics (TGTX) Stock Down 50% Today?
Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. S more_horizontal

By Seeking Alpha
July 29, 2023
TG Therapeutics: Addressing The SC Ocrevus Concern
The launch of Briumvi is off to a solid start, but the stock pulled back recently and fell more after Roche reported positive phase 3 results of subcu more_horizontal